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Successful novel treatment of Schamberg’s purpura with
colchicine
Novo tratamento bem-sucedido da púrpura de Schamberg com colchicina
Mario Geller*
CASE REPORT
ABSTRACT
Schamberg’s disease is a rare condition that predominantly
involves the lower extremities. A caucasian female patient with
recurrent episodes of diffuse and painless purpuric skin eruptions
in the lower extremities is presented. A skin biopsy along with the
clinical appearance made the diagnosis of Schamberg’s disease.
She was treated with colchicine (0.5 mg twice a day) and within a
week showed complete disappearance of all purpuric eruptions.
Colchicine was taken for the next 6 months and then discontinued.
Three months later she was well without any recurrences.
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RESUMO
A doença de Schamberg é uma condição rara que envolve
predominantemente as extremidades inferiores. É apresentado
um caso de paciente do sexo feminino, branca, com episódios
recorrentes de lesões cutâneas purpúricas não dolorosas nas
extremidades inferiores. Uma biópsia de pele, juntamente com o
quadro clínico, fizeram o diagnóstico de doença de Schamberg. Foi
instituído o tratamento com colchicina (0,5 mg duas vezes ao dia)
e dentro de uma semana as lesões purpúricas desapareceram
completamente. A colchicina foi administrada durante 6 meses e
depois descontinuada. Três meses mais tarde a paciente se
apresentava bem, sem qualquer recorrência.
Descritores: Transtornos da pigmentação/quimioterapia; Púrpura
de Schoenlein-Henoch/quimioterapia; Colchicina/uso terapêutico
INTRODUCTION
Schamberg’s disease belongs to the spectrum of the
non-thrombocytopenic purpura simplex. This condition
shows the histologic picture of inflammation and
hemorrhage without fibrinoid necrosis of vessels. The
vascular damage and erythrocyte leakage are secondary
to localized T cell-mediated reactions in the vicinity
of dermal capillaries. Cytokines and increased
expression of endothelial adhesion molecules might
promote T cell-keratinocyte adherence. The early
activation of these adhesion receptors may determine
the pattern of organization of the pericapillary
inflammatory infiltrate(1).
CASE REPORT
A 29-year-old Caucasian female presented with
recurrent episodes of diffuse and painless purpuric skin
eruptions in the lower extremities for the last 5 months.
No constitutional or rheumatic manifestations were
present. Physical examination revealed several small
purpuric pigmented lesions present on both legs and
feet. No other findings were noted. A skin punch biopsy
showed the characteristic lymphocytic perivasculitis and
erythrocyte leakage of Schamberg’s disease. Laboratory
data including complete blood count, differential,
reticulocyte and platelet counts, routine biochemistry,
serum ferritin, iron and total iron binding capacity,
serum protein electrophoresis, C reactive protein, anti-
streptolysin O, rheumatoid factor, cryoglobulins,
cryofibrinogen, complete coagulogram, spine films, and
venous doppler of the lower limbs, were all negative or
within normal limits. Previously she did not improve
on several bursts of oral prednisone (40 to 60 mg/day)
and pentoxifylline (1.2 g/day). She was then given a
sole trial of oral colchicine (0.5 mg twice a day), and
an excellent clinical response was obtained, within one
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week, with progressive and complete disappearance of
all purpuric eruptions. Colchicine was taken for the
next 6 months and then discontinued. The patient is
now off colchicine for 3 months without any recurrences
of Schamberg’s purpura (figura 1).
DISCUSSION
The etiology of this rare lymphocytic pigmented
purpuric capillaritis remains unknown. So far there is
no effective treatment for Schamberg’s purpura. There
is general agreement on trying anti-inflammatory
modulators in the treatment of immunologically
mediated skin disorders(2,3). We previously reported that
colchicine might be beneficial in the control of
Schamberg’s purpura(4). The patient discontinued
colchicine four years ago and purpura has not recurred.
Therefore, we decided to try it again in another patient
with similar features.
Figure 1. Disappearance of Schamberg’s purpura of lower extremities after 6 months of oral colchicine.
CONCLUSIONS
Schamberg’s disease is still considered idiopathic and
has no established therapy. For the second time, we
report the successful treatment of this affection with
oral colchicine given for 6 months. Apparently it also
prevents future relapses.
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